Miyake Katsunori, Li Feng, Tezuka Yasuhiro, Awale Suresh, Kadota Shigetoshi
Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
Nat Prod Commun. 2010 Jul;5(7):1009-12.
Twenty-four quassinoids isolated from Eurycoma longifolia Jack were investigated for their cytotoxicity against a panel of four different cancer cell lines, which includes three murine cell lines [colon 26-L5 carcinoma (colon 26-L5), B16-BL6 melanoma (B16-BL6), Lewis lung carcinoma (LLC)] and a human lung A549 adenocarcinoma (A549) cell line. Among the tested compounds, eurycomalactone (9) displayed the most potent activity against all the tested cell lines; colon 26-L5 (IC50 = 0.70 microM), B16-BL6 (IC50 = 0.59 microM), LLC (IC50 = 0.78 microM), and A549 (IC50 = 0.73 microM). These activities were comparable to clinically used anticancer agent doxorubicin (colon 26-L5, IC50 = 0.76 microM; B16-BL6, IC50 = 0.86 microM; LLC, IC50 = 0.80 microM; A549, IC50 = 0.66 microM).
对从长叶刺蒺藜中分离出的24种苦木素类化合物进行了研究,考察它们对一组四种不同癌细胞系的细胞毒性,这组细胞系包括三种鼠源细胞系[结肠26-L5癌(结肠26-L5)、B16-BL6黑色素瘤(B16-BL6)、Lewis肺癌(LLC)]和一种人肺A549腺癌(A549)细胞系。在测试的化合物中,刺蒺藜内酯(9)对所有测试细胞系表现出最强的活性;对结肠26-L5(IC50 = 0.70微摩尔)、B16-BL6(IC50 = 0.59微摩尔)、LLC(IC50 = 0.78微摩尔)和A549(IC50 = 0.73微摩尔)。这些活性与临床使用的抗癌药物阿霉素相当(结肠26-L5,IC50 = 0.76微摩尔;B16-BL6,IC50 = 0.86微摩尔;LLC,IC50 = 0.80微摩尔;A549,IC50 = 0.66微摩尔)。